Journal article · 2022 · Open access

Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial

Taisei Masuda, Kyoko Murakami, Kenkichi Sugiura, Sho Sakui, Ron P. Schuring, Mitsuhiro Mori

Vaccine, 40(24), 3380–3388 · Published 29 April 2022 · DOI 10.1016/j.vaccine.2022.04.035

Open PDFView at the publisherCite this paper

In brief

“Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial” is a 2022 journal article by Taisei Masuda and 5 co-authors, published in Vaccine. OpenAlex counts 20 citations as of 20 November 2026, which puts it in the top 9% of works published in 2022 by citations. It is open access under a CC BY licence: the full text is free to read at Vaccine.

Citations
20
Most cited in
2023 (11)
Field-weighted impact
2.20
References
8
Authors
6

Abstract

BACKGROUND: We evaluated the safety and immunogenicity of NVX-CoV2373, a recombinant SARS-CoV-2 nanoparticle vaccine, in healthy Japanese participants. METHODS: This phase 1/2, randomized, observer-blind, placebo-controlled trial conducted in Japan (two sites), enrolled healthy Japanese adults aged ≥ 20 years with no history/risk of SARS-CoV-2 infection and no prior exposure to other approved/investigational SARS-CoV-2 vaccines or treatments. Participants were stratified by age (< 65 or ≥ 65 years) and randomized to receive two doses of either NVX-CoV2373 (5 μg SARS-CoV-2 rS; 50 μg Matrix-M1) or placebo, 21 days apart. Primary outcomes were safety and immunogenicity assessed by serum IgG antibody levels against SARS-CoV-2 rS protein on day 36. Herein, we report the primary data analysis at 4 weeks after the second dose, ahead of 12-month follow-up completion (data cut-off: 8 May 2021). RESULTS: Between 12 February 2021 and 17 March 2021, 326 subjects were screened, and 200 participants enrolled and randomized: NVX-CoV2373, n = 150; placebo, n = 50. Solicited adverse events (AEs) through 7 days after each injection occurred in 121/150 (80.7%) and 11/50 (22.0%) participants in the NVX-CoV2373 and placebo arms, respectively. In the NVX-CoV2373 arm, tenderness and injection site pain were the most frequently reported solicited AEs after each vaccination, irrespective of age. Robust immune responses occurred with NVX-CoV2373 (n = 150) by day 36: IgG geometric mean fold rise (95% confidence interval) 259 (219, 306); seroconversion rate 100% (97.6, 100). No such response occurred with placebo (n = 49). CONCLUSION: Two doses of NVX-CoV2373 given with a 21-day interval demonstrated acceptable safety and induced robust anti-SARS-CoV-2 immune responses in healthy Japanese adults. FUNDING: Takeda Pharmaceutical Company Limited and Japan Agency for Medical Research and Development (AMED). CLINICALTRIALS: gov identifier: NCT04712110.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Masuda, T., Murakami, K., Sugiura, K., Sakui, S., Schuring, R. P., & Mori, M. (2022). Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial. Vaccine, 40(24), 3380–3388. https://doi.org/10.1016/j.vaccine.2022.04.035

MLA 9

Masuda, Taisei, et al. “Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.” Vaccine, vol. 40, no. 24, 2022, pp. 3380–3388. https://doi.org/10.1016/j.vaccine.2022.04.035.

Chicago

Masuda, Taisei, Kyoko Murakami, Kenkichi Sugiura, Sho Sakui, Ron P. Schuring, and Mitsuhiro Mori. 2022. “Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.” Vaccine 40 (24): 3380–3388. https://doi.org/10.1016/j.vaccine.2022.04.035.

Harvard

Masuda, T. et al. (2022) ‘Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial’, Vaccine, 40(24), pp. 3380–3388. doi:10.1016/j.vaccine.2022.04.035.

IEEE

T. Masuda, K. Murakami, K. Sugiura, S. Sakui, R. P. Schuring, and M. Mori, “Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial,” Vaccine, vol. 40, no. 24, pp. 3380–3388, 2022, doi: 10.1016/j.vaccine.2022.04.035.

BibTeX

@article{masuda2022safety,
  title     = {{Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial}},
  author    = {Masuda, Taisei and Murakami, Kyoko and Sugiura, Kenkichi and Sakui, Sho and Schuring, Ron P. and Mori, Mitsuhiro},
  journal   = {Vaccine},
  year      = {2022},
  volume    = {40},
  number    = {24},
  pages     = {3380--3388},
  doi       = {10.1016/j.vaccine.2022.04.035},
  url       = {https://doi.org/10.1016/j.vaccine.2022.04.035}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202233
20231111
202433
202522
202611

Its field-weighted citation impact is 2.20: it has been cited 2.20 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research

  • NVX-CoV2373
  • COVID-19 vaccines
  • vaccine safety
  • immunogenicity
  • IgG antibody response
  • seroconversion
  • healthy adults
  • Japanese adults

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Masuda, T., Murakami, K., Sugiura, K., Sakui, S., Schuring, R. P., & Mori, M. (2022). Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial. Vaccine, 40(24), 3380–3388. https://doi.org/10.1016/j.vaccine.2022.04.035

How many times has this paper been cited?

20 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Vaccine: sign in and open the PDF from this page.

Who wrote this paper?

Taisei Masuda, Kyoko Murakami, Kenkichi Sugiura, Sho Sakui, Ron P. Schuring, Mitsuhiro Mori.

What is the DOI of this paper?

10.1016/j.vaccine.2022.04.035, permanently at https://doi.org/10.1016/j.vaccine.2022.04.035. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.